GERN - NASDAQ

Geron Corporation

GERN·NASDAQ

$1.16

-0.85%

HealthcareBiotechnology

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$744.16M

EPS-0.1300

P/E Ratio-8.92

Earnings Date08/05/2026

570.54M

Assets

-4%

3Y+199.0%

5Y+111.0%

10Y+338.0%

344.67M

Total Liabilities

10%

3Y+212.0%

5Y+477.0%

10Y+4280.0%

225.87M

Total Equity

-19%

3Y+182.0%

5Y+7.0%

10Y+85.0%

Geron Corporation Funding & Solvency Profile

GERN · NASDAQ

Current Assets

Cash & Cash Equivalents79.44M

Net Receivables39.23M

Inventory0.00

Other Current Assets121.25M

Total Current Assets520 M

Non-Current Assets

Property, Plant & Equipment884.00K

Goodwill & Intangible Assets0.00

Long-Term Investments41.29M

Other Non-Current Assets8.10M

Total Non-Current Assets50 M

Total Assets

570.54M

Financial Health Analysis

Current Ratio

4.66x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.53x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

409 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

91% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Geron Corporation Balance Sheet

GERN • NASDAQ

Geron Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	79.4M	79M	70M	56.8M	34.9M	9.9M	13.6M	10.8M	16.6M	13.1M	21.5M	43.1M	13M	22.9M	16.1M	46M	34.6M	109.3M	146M	135.9M
Short-Term Investments	280.4M	327.6M	263.7M	115.9M	148.9M	186.4M	125.7M	152.7M	78.4M	102M	92.5M	108.6M	52.2M	73.5M	105.2M	140.6M	77M	53.5M	60M	77.4M
Cash & Short-Term Investments	359.8M	406.6M	333.7M	172.7M	183.7M	196.3M	139.3M	163.6M	95M	115.1M	114M	151.7M	65.2M	96.3M	121.3M	186.6M	111.6M	162.8M	206M	213.3M
Net Receivables	39.2M	38.8M	1.7M	3.1M	1.8M	722K	802K	1.2M	436K	475K	1.2M	963K	564K	752K	1.4M	1.8M	1.3M	882K	788K	1.3M
Accounts Receivables	37M	35.9M	0.0	3.1M	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	963K	564K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	2.2M	2.9M	1.7M	0.0	0.0	722K	0.0	1.2M	436K	475K	1.2M	0.0	0.0	752K	1.4M	1.8M	1.3M	882K	788K	1.3M
Inventory	0.0	38.7M	0.0	0.0	0.0	0.0	0.0	-1.2M	-436K	-475K	-1.2M	-963K	0.0	-752K	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	1.4M	2.5M	1.2M	1.3M	580K	524K	647K	736K	474K	1.3M	2.1M	5.9M	4.1M	3.7M	4.1M	2M
Other Current Assets	121.2M	6.9M	6M	4.4M	364K	363K	270K	269K	268K	268K	267K	266K	795K	794K	793K	792K	791K	816K	2.4M	0.0
Total Current Assets	520.3M	491M	341.3M	180.2M	187.2M	199.9M	141.6M	166.1M	96M	116.1M	115.9M	153.4M	67.1M	98.4M	125.6M	195M	117.8M	168.2M	213.4M	217.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	884K	4.2M	4.7M	4.9M	5.4M	6M	2.9M	59K	102K	183K	207K	173K	92K	974K	1.2M	3.1M	3.9M	4.4M	4.1M	2.5M
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	188K
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	188K
Long-Term Investments	41.3M	94.5M	43.3M	0.0	28.7M	63.4M	19.7M	18.6M	14.2M	14M	32.7M	18.9M	0.0	0.0	32.1M	34.4M	56M	1M	55K	220K
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-408K
Other Non-Current Assets	8.1M	4.1M	4.7M	5.4M	4.8M	1.5M	1.4M	585K	0.0	0.0	0.0	0.0	195K	410K	1M	1.1M	2.7M	2.6M	1.4M	1.2M
Total Non-Current Assets	50.3M	102.8M	52.7M	10.3M	38.8M	70.9M	23.9M	19.2M	14.3M	14.1M	32.9M	19.1M	287K	1.4M	34.4M	38.6M	62.6M	8M	5.5M	3.6M
Total Assets	570.5M	593.8M	394.1M	190.6M	226M	270.7M	165.5M	185.3M	110.3M	130.2M	148.8M	172.5M	67.3M	99.8M	160M	233.6M	180.4M	176.2M	218.9M	220.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	11.3M	8.6M	6.2M	10.2M	6.7M	6.9M	15.5M	982K	503K	225K	160K	1M	1.4M	3.4M	3M	3.5M	2.2M	2.9M	2.9M	2M
Accounts Payable	11.3M	8.6M	6.2M	10.2M	6.7M	6.9M	1.2M	982K	503K	225K	160K	1M	1.4M	3.4M	3M	3.5M	2.2M	2.4M	2.9M	2M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	14.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	440K	0.0	0.0
Accrued Expenses	0.0	35.5M	40.3M	33.1M	29.8M	14.9M	7.5M	3M	3.7M	7.6M	6.5M	4.2M	3.9M	5.2M	3M	8.8M	3.7M	3.6M	6.7M	5.2M
Short Term Debt	18.4M	0.0	46.9M	20.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	1M	974K	949K	925K	901K	878K	354K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	35M	0.0	0.0	0.0	350K	700K	27K	241K	1.2M
Other Current Liabilities	80.8M	43.2M	13.8M	11.5M	8.1M	8.2M	4.8M	3.6M	2.4M	0.0	0.0	1.6M	2.2M	5.5M	7.4M	28.2M	897K	1.2M	2.9M	38.5M
Total Current Liabilities	111.5M	88.3M	108.1M	76.7M	45.5M	30.9M	28.2M	7.6M	6.5M	7.9M	6.6M	41.8M	7.6M	14.1M	13.4M	40.8M	7.5M	7.7M	12.7M	46.8M
NON-CURRENT LIABILITIES
Long Term Debt	231.7M	118.5M	35.1M	30.2M	49.8M	24M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	350K	52K	78K	954K
Other Non-Current Liabilities	0.0	104.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	427K	0.0
Total Non-Current Liabilities	233.1M	225.2M	38.1M	33.9M	54.1M	28.8M	2.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	350K	52K	505K	105K
Capital Lease Obligations	2.4M	3.2M	4M	4.6M	5.2M	5.7M	2.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	344.7M	313.5M	146.1M	110.6M	99.6M	59.8M	30.4M	7.6M	6.5M	7.9M	6.6M	41.8M	7.6M	14.1M	13.4M	40.8M	7.8M	7.8M	13.2M	46.9M
SHAREHOLDERS' EQUITY
Common Stock	640K	606K	545K	390K	324K	310K	200K	186K	160K	159K	159K	157K	131K	130K	131K	123K	92K	81K	76K	70K
Additional Paid-In Capital	2.1B	2.1B	1.8B	1.5B	1.4B	1.4B	1.2B	1.2B	1.1B	1.1B	1.1B	1.1B	952.4M	939.9M	932.1M	881.4M	750.2M	675.2M	650.4M	573.2M
Retained Earnings	-1.9B	-1.8B	-1.6B	-1.4B	-1.3B	-1.2B	-1.1B	-1B	-985.8M	-957.9M	-928.4M	-928.4M	-892.8M	-854.4M	-785.5M	-688.7M	-577.3M	-506.9M	-444.9M	-399.1M
Accumulated Other Comprehensive Income/Loss	269K	261K	185K	-219K	-173K	78K	132K	-183K	-207K	-53K	-213K	-84K	-14K	40K	-91K	-96K	-406K	40K	33K	-213K
Total Stockholders' Equity	225.9M	280.3M	247.9M	80M	126.4M	210.9M	135.2M	177.7M	103.8M	122.4M	142.1M	130.7M	59.8M	85.7M	146.6M	192.7M	172.6M	168.5M	205.7M	173.9M
Total Equity	225.9M	280.3M	247.9M	80M	126.4M	210.9M	135.2M	177.7M	103.8M	122.4M	142.1M	130.7M	59.8M	85.7M	146.6M	192.7M	172.6M	168.5M	205.7M	173.9M
SUMMARY
Total Liabilities & Equity	570.5M	593.8M	394.1M	190.6M	226M	270.7M	165.5M	185.3M	110.3M	130.2M	148.8M	172.5M	67.3M	99.8M	160M	233.6M	180.4M	176.2M	218.9M	220.8M
Total Investments	321.6M	422.1M	307M	115.9M	177.5M	249.7M	145.3M	171.3M	92.6M	116M	125.2M	127.6M	52.2M	73.5M	137.3M	175M	133M	54.5M	60M	77.7M
Total Debt	251.6M	121.7M	85.9M	55.8M	55M	29.7M	2.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	172.1M	42.7M	15.9M	-1.1M	20.1M	19.8M	-11.1M	-10.8M	-16.6M	-13.1M	-21.5M	-43.1M	-13M	-22.9M	-16.1M	-46M	-34.6M	-109.3M	-146M	-135.9M
Shares Outstanding	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000	638,355,000

SEC Filings

GERN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 27, 2026	May 20, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 07, 2026	May 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 25, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 06, 2026	January 05, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 16, 2025	December 10, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 07, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 574 filings

Related Guides

Blog Categories

Continue your GERN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.